Reference SummaryMahler JF, Toxicol Pathol 1998 Jul-Aug;26(4):501-11
Title |
Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. |
Authors |
Mahler JF; Flagler ND; Malarkey DE; Mann PC; Haseman JK; Eastin W |
Journal |
Toxicol Pathol |
Volume |
26 |
Issue |
4 |
Year |
1998 |
Pages |
501-11 |
Abstract |
Recently, the use of selected genetically altered mouse models in the detection of carcinogens after short-term chemical exposures has been evaluated. Studies of several chemicals conducted by the National Toxicology Program in Tg.AC transgenic and heterozygous p53-deficient mice have been completed recently and represent a major contribution to this effort, as well as the largest accumulation to date of toxicologic pathology data in these 2 lines of mice. The purpose of this report is to describe the proliferative target organ effects observed in this set of studies, as well as to present the tumor profile in the control groups of this data set. These findings provide a comprehensive toxicologic assessment of these 2 genetically altered mouse strains, which are of emerging importance in toxicologic pathology. |
Links |
J:51448 – MGI References 9715509 – National Library of Medicine/PubMed |
| Strain | Model Name | Treatment Agent(s) | Organ Affected | Frequency | Model Details |
|---|---|---|---|---|---|
| B6.129S7-Trp53tm1Brd/+ | Bone osteosarcoma | Bone - Jaw |
0 - 1.9 |
||
| B6.129S7-Trp53tm1Brd/+ | Connective tissue - Fibroblast fibrosarcoma | Urinary bladder |
0 - 0.9 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Connective tissue - Ligament tumor | Bone - Jaw |
observed |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Erythrocyte leukemia - erythroleukemia | Erythrocyte |
0.6 - 2.2 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Erythrocyte leukemia - erythroleukemia | Liver |
observed |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Forestomach papilloma | Forestomach |
7.4 - 10.3 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Forestomach squamous cell carcinoma | Forestomach |
0 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Forestomach squamous cell papilloma |
|
Forestomach |
observed |
|
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Intestine - Small Intestine carcinoma | Intestine - Small Intestine |
0 - 0.5 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Leukocyte - Monocyte - Macrophage - Histiocyte histiocytic sarcoma | Uterus |
0.5 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Leukocyte - Myelocyte (Granulocyte) - Basophil - Mast cell tumor | Subcutis |
0 - 0.5 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Leukocyte - Myelocyte (Granulocyte) dysplasia |
|
Leukocyte - Myelocyte (Granulocyte) |
observed |
|
| B6.129S7-Trp53tm1Brd/+ | Leukocyte - Myelocyte (Granulocyte) leukemia - myelocytic | Leukocyte - Myelocyte (Granulocyte) |
0 - 0.9 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Leukocyte lymphoma | Leukocyte |
0 - 1.1 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Leukocyte lymphoma |
|
Leukocyte |
observed |
|
| B6.129S7-Trp53tm1Brd/+ | Leukocyte lymphoma | Leukocyte |
1.8 - 1.9 |
||
| B6.129S7-Trp53tm1Brd/+ | Leukocyte lymphoma |
|
Leukocyte |
observed |
|
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Lung adenoma | Lung |
1.6 - 4.3 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Lung adenoma |
|
Lung |
observed |
|
| B6.129S7-Trp53tm1Brd/+ | Lung adenoma | Lung |
0 - 0.9 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Lung carcinoma | Lung |
0 - 0.5 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Lung carcinoma |
|
Lung |
observed |
|
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Lung hyperplasia |
|
Lung |
observed |
|
| B6.129S7-Trp53tm1Brd/+ | Mesodermal cell/mesoblast sarcoma | Subcutis |
1.9 - 3.7 |
||
| B6.129S7-Trp53tm1Brd/+ | Mesodermal cell/mesoblast sarcoma | CNS - Meninges |
0 - 0.9 |
||
| B6.129S7-Trp53tm1Brd/+ | Mesodermal cell/mesoblast sarcoma |
|
Subcutis |
observed |
|
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Ovary - Germ cell teratoma | Ovary - Germ cell |
1.6 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Salivary gland - Salivary duct - Submandibular squamous cell carcinoma | Salivary gland - Salivary duct - Submandibular |
observed |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Salivary gland - Salivary duct squamous cell carcinoma | Salivary gland - Salivary duct |
1.2 - 2.2 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Skin carcinoma - spindle cell |
|
Skin |
observed |
|
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Skin keratoacanthoma |
|
Skin |
observed |
|
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Skin squamous cell carcinoma | Skin |
0 - 0.5 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Skin squamous cell carcinoma |
|
Skin |
observed |
|
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Skin squamous cell papilloma | Skin |
3.7 - 3.8 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Skin squamous cell papilloma |
|
Skin |
observed |
|
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Tooth ameloblastoma | Bone - Jaw |
observed |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Tooth odontoma | Bone - Jaw |
observed |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Tooth tumor | Bone - Jaw |
observed - 17.3 |
||
| FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed | Uterus - Endometrium adenoma | Uterus - Endometrium |
0.5 |